Skip to main content

Advertisement

SpringerLink
Log in

Prognostic factors for anaplastic astrocytomas

  • Clinical–Patient Studies
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Anaplastic astrocytomas (WHO grade III) constitute about 10% of all gliomas. Definitive data on predictive and prognostic factors are lacking for these neoplasms that are considered the most enigmatic entity among the whole spectrum of astrocytic tumors because of their unclear biologic behavior and variable clinical outcome. Currently, only few factors have been identified as useful for prognosis of anaplastic astrocytoma: age and Karnofsky Performance Status. Attempts have been made to identify biological prognostic factors for response to therapy and clinical outcome, as well as potential targets for new therapies. Potential prognostic biomarkers concern tumor suppressor genes on chromosome 9q that are involved in the RB1 pathway; PTEN, the PI3k/Akt/p70s6k cascade, survivin gene, Formylpeptide receptor, minichromosome maintenance protein 3 and genes on chromosome 7. Furthermore, some angiogenic factors (e.g. hypoxia-inducible factor-1α, vascular endothelial growth factor and scatter factor/hepatocyte growth factor) and the methylation status of O6-methylguanine-DNA methyltransferase gene (one of the main effectors of DNA repair system) are emerging novel putative determinants of prognosis. Moreover, recent studies on magnetic resonance imaging characteristics give prognostic significance to the presence of necrosis and enhancement. The state of the art pictured here underlie the recent interest on gene expression profile to identify aberrations useful to understand the biologic behavior of astrocytic tumors. Our knowledge in this field is still limited, and remains an issue of great concern.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Silverberg E, Boring CC, Squires TS (1990) Cancer statistics, 1990. CA Cancer J Clin 40:9–26

    PubMed  CAS  Google Scholar 

  2. Kleihues P, Cavenee WK (2000) World Health Classification of Tumors. Tumors of the nervous system. Pathology and Genetics. IARC Scientific Publications, Lyon

    Google Scholar 

  3. Louis DN, Holland EC, Cairncross JG (2001) Glioma classification: a molecular reappraisal. Am J Pathol 159:779–786

    PubMed  CAS  Google Scholar 

  4. Vertosick FT Jr, Selker RG, Arena VC (1991) Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography. Neurosurgery 28:496–501

    Article  PubMed  Google Scholar 

  5. McCormack BM, Miller DC, Budzilovich GN et al (1992) Treatment and survival of low-grade astrocytoma in adults—1977–1988. Neurosurgery 31:636–642; discussion 642

    Article  PubMed  CAS  Google Scholar 

  6. Daumas-Duport C, Scheithauer B, O’Fallon J et al (1988) Grading of astrocytomas. A simple and reproducible method. Cancer 62:2152–2165

    Article  PubMed  CAS  Google Scholar 

  7. Kleihues P, Louis DN, Scheithauer BW et al (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215–225; discussion 226–219

    PubMed  Google Scholar 

  8. Perry A, Jenkins RB, O’Fallon JR et al (1999) Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors. An analysis of DNA content (ploidy), cellular proliferation, and p53 expression. Cancer 86:672–683

    Article  PubMed  CAS  Google Scholar 

  9. Tortosa A, Vinolas N, Villa S et al (2003) Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 97:1063–1071

    Article  PubMed  Google Scholar 

  10. Curran WJ Jr, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710

    Article  PubMed  Google Scholar 

  11. Kunwar S, Mohapatra G, Bollen A et al (2001) Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival. Cancer Res 61:7683–7688

    PubMed  CAS  Google Scholar 

  12. Schwartz SA, Weil RJ, Thompson RC et al (2005) Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 65:7674–7681

    PubMed  CAS  Google Scholar 

  13. Sallinen PK, Sallinen SL, Helen PT et al (2000) Grading of diffusely infiltrating astrocytomas by quantitative histopathology, cell proliferation and image cytometric DNA analysis. Comparison of 133 tumors in the context of the WHO 1979 and WHO 1993 grading schemes. Neuropathol Appl Neurobiol 26:319–331

    Article  PubMed  CAS  Google Scholar 

  14. Burger PC, Vogel FS, Green SB et al (1985) Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 56:1106–1111

    CAS  Google Scholar 

  15. Barker FG, II, Davis RL, Chang SM et al (1996) Necrosis as a prognostic factor in glioblastoma multiforme. Cancer 77:1161–1166

    Article  PubMed  Google Scholar 

  16. Pope WB, Sayre J, Perlina A et al (2005) MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 26:2466–2474

    PubMed  Google Scholar 

  17. Korshunov A, Golanov A, Sycheva R (2002) Immunohistochemical markers for prognosis of anaplastic astrocytomas. J Neurooncol 58:203–215

    Article  PubMed  Google Scholar 

  18. Backlund LM, Nilsson BR, Goike HM et al (2003) Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clin Cancer Res 9:4151–4158

    PubMed  Google Scholar 

  19. Backlund LM, Nilsson BR, Liu L et al (2005) Mutations in Rb1 pathway-related genes are associated with poor prognosis in anaplastic astrocytomas. Br J Cancer 93:124–130

    Article  PubMed  CAS  Google Scholar 

  20. Albarosa R, Colombo BM, Roz L et al (1996) Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q. Am J Hum Genet 58:1260–1267

    PubMed  CAS  Google Scholar 

  21. Rasheed BK, McLendon RE, Friedman HS et al (1995) Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene 10:2243–2246

    PubMed  CAS  Google Scholar 

  22. Li J, Yen C, Liaw D et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943–1947

    Article  PubMed  CAS  Google Scholar 

  23. Steck PA, Pershouse MA, Jasser SA et al (1997) Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356–362

    Article  PubMed  CAS  Google Scholar 

  24. Smith JS, Tachibana I, Passe SM et al (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246–1256

    Article  PubMed  CAS  Google Scholar 

  25. Chakravarti A, Zhai G, Suzuki Y et al. (2004) The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22:1926–1933

    Article  PubMed  CAS  Google Scholar 

  26. Chakravarti A, Noll E, Black PM et al (2002) Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20:1063–1068

    Article  PubMed  CAS  Google Scholar 

  27. Zhen HN, Zhang X, Hu PZ et al (2005) Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer 104:2775–2783

    Article  PubMed  CAS  Google Scholar 

  28. Jensen RL, Ragel BT, Whang K et al (2006) Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J Neurooncol (in press)

  29. Korkolopoulou P, Patsouris E, Konstantinidou AE et al (2004) Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol Appl Neurobiol 30:267–278

    Article  PubMed  CAS  Google Scholar 

  30. Abounader R, Laterra J (2005) Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neurooncol 7:436–451

    CAS  Google Scholar 

  31. Zhou Y, Bian X, Le Y et al (2005) Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. J Natl Cancer Inst 97:823–835

    Article  PubMed  CAS  Google Scholar 

  32. El-Rayes BF, Norton CS, Sakr W et al (2005) Cellular DNA content parameters as prognostic indicators in human astrocytomas. J Neurooncol 71:85–89

    Article  PubMed  CAS  Google Scholar 

  33. Sallinen PK, Haapasalo HK, Visakorpi T et al (1994) Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 174:275–282

    Article  PubMed  CAS  Google Scholar 

  34. Reavey-Cantwell JF, Haroun RI, Zahurak M et al (2001) The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. J Neurooncol 55:195–204

    Article  PubMed  CAS  Google Scholar 

  35. Mohapatra G, Kim DH, Feuerstein BG (1995) Detection of multiple gains and losses of genetic material in ten glioma cell lines by comparative genomic hybridization. Genes Chromosomes Cancer 13:86–93

    Article  PubMed  CAS  Google Scholar 

  36. Mohapatra G, Bollen AW, Kim DH et al (1998) Genetic analysis of glioblastoma multiforme provides evidence for subgroups within the grade. Genes Chromosomes Cancer 21:195–206

    Article  PubMed  CAS  Google Scholar 

  37. Weber RG, Sabel M, Reifenberger J et al (1996) Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. Oncogene 13:983–994

    PubMed  CAS  Google Scholar 

  38. Schlegel J, Scherthan H, Arens N et al (1996) Detection of complex genetic alterations in human glioblastoma multiforme using comparative genomic hybridization. J Neuropathol Exp Neurol 55:81–87

    Article  PubMed  CAS  Google Scholar 

  39. Harada K, Nishizaki T, Ozaki S et al. (1998) Intratumoral cytogenetic heterogeneity detected by comparative genomic hybridization and laser scanning cytometry in human gliomas. Cancer Res 58:4694–4700

    PubMed  CAS  Google Scholar 

  40. Nishizaki T, Ozaki S, Harada K et al (1998) Investigation of genetic alterations associated with the grade of astrocytic tumor by comparative genomic hybridization. Genes Chromosomes Cancer 21:340–346

    Article  PubMed  CAS  Google Scholar 

  41. Chumbalkar VC, Subhashini C, Dhople VM et al (2005) Differential protein expression in human gliomas and molecular insights. Proteomics 5:1167–1177

    Article  PubMed  CAS  Google Scholar 

  42. Soling A, Sackewitz M, Volkmar M et al (2005) Minichromosome maintenance protein 3 elicits a cancer-restricted immune response in patients with brain malignancies and is a strong independent predictor of survival in patients with anaplastic astrocytoma. Clin Cancer Res 11:249–258

    PubMed  Google Scholar 

  43. Kamiryo T, Tada K, Shiraishi S et al (2004) Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery 54:349–357; discussion 357

    Article  PubMed  Google Scholar 

  44. Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354

    Article  PubMed  CAS  Google Scholar 

  45. Hegi ME, Diserens AC, Godard S et al (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871–1874

    Article  PubMed  CAS  Google Scholar 

  46. Balana C, Ramirez JL, Taron M et al (2003) O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 9:1461–1468

    PubMed  CAS  Google Scholar 

  47. Paz MF, Yaya-Tur R, Rojas-Marcos I et al (2004) CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10:4933–4938

    Article  PubMed  CAS  Google Scholar 

  48. Blanc JL, Wager M, Guilhot J et al (2004) Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 68:275–283

    Article  PubMed  CAS  Google Scholar 

  49. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003

    Article  PubMed  CAS  Google Scholar 

  50. Brell M, Tortosa A, Verger E et al (2005) Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 11:5167–5174

    Article  PubMed  CAS  Google Scholar 

  51. Nutt CL, Mani DR, Betensky RA et al (2003) Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63:1602–1607

    PubMed  CAS  Google Scholar 

  52. Freije WA, Castro-Vargas FE, Fang Z et al (2004) Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64:6503–6510

    Article  PubMed  CAS  Google Scholar 

  53. Pronin IN, Holodny AI, Petraikin AV (1997) MRI of high-grade glial tumors: correlation between the degree of contrast enhancement and the volume of surrounding edema. Neuroradiology 39:348–350

    Article  PubMed  CAS  Google Scholar 

  54. Hamstra DA, Chenevert TL, Moffat BA et al (2005) Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci USA 102:16759–16764

    Article  PubMed  CAS  Google Scholar 

  55. Bergsland EK (2006) When does the presence of the target predict response to the targeted agent? J Clin Oncol 24:213–216

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Istituto Oncologico Veneto-IRCCS, Padova, Italy

    Alessia Compostella, Alicia Tosoni & Valeria Blatt

  2. Department of Medical Oncology, Bellaria Hospital, Via Altura, 3, 40139, Bologna, Italy

    Enrico Franceschi & Alba A. Brandes

Authors
  1. Alessia Compostella
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alicia Tosoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valeria Blatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Enrico Franceschi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alba A. Brandes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alba A. Brandes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Compostella, A., Tosoni, A., Blatt, V. et al. Prognostic factors for anaplastic astrocytomas. J Neurooncol 81, 295–303 (2007). https://doi.org/10.1007/s11060-006-9232-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-006-9232-z

Keywords

Search

Navigation